Erratum: Ethosuximide ameliorates neurodegenerative disease phenotypes by modulating DAF-16/FOXO target gene expression (Molecular Neurodegeneration (2015) 10:51 DOI: 10.1186/s13024-015-0046-3);Ethosuximide ameliorates neurodegenerative disease phenotypes by modulating DAF-16/FOXO target gene expression

Molecular Neurodegeneration

Volumn 10, Issue 1, 2015, Pages

  Chen, Xi ^a,c   McCuef, Hannah V ^a   Wong, Shi Quan ^a   Kashyap, Sudhanva S ^a   Kraemer, Brian C ^b   Barclay, Jeff W ^a   Burgoyne, Robert D ^a   Morgan, Alan ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Adult onset neuronal lipofuscinosis; Aging; Caenorhabditis elegans; Frontotemporal dementia; Neuroblastoma; Neurodegeneration

Indexed keywords

CALCIUM CHANNEL T TYPE; ETHOSUXIMIDE; TAU PROTEIN; TRANSCRIPTION FACTOR DAF 16; TRANSCRIPTION FACTOR FOXO; CAENORHABDITIS ELEGANS PROTEIN; DAF-16 PROTEIN, C ELEGANS; FORKHEAD TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR;

ADULT ONSET NEURONAL CEROID LIPOFUSCINOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; BACTERIAL STRAIN; CAENORHABDITIS ELEGANS; CHEMOSENSORY DEFECT; CONTROLLED STUDY; DAF 16 GENE; DEGENERATIVE DISEASE; DNAJC5 GENE; DNJ 14 GENE; DOWN REGULATION; DRUG EFFICACY; DRUG RESPONSE; ESCHERICHIA COLI; FOOD; FOXO GENE; FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL DEMENTIA WITH PARKINSONISM 17 TAUOPATHY; GENE; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; HUMAN; LIFESPAN; LOCOMOTION IMPAIRMENT; MALE; MAMMAL; MOTOR DYSFUNCTION; NERVE CELL; NEURONAL CEROID LIPOFUSCINOSIS; NEUROPROTECTION; NONHUMAN; PARKINSONISM; PARKINSONISM 17; PATHOGENESIS; PHENOTYPE; PROTEIN AGGREGATION; RNA INTERFERENCE; SENSORY DYSFUNCTION; TAUOPATHY; THERAPY EFFECT; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; UPREGULATION; WORM; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; SIGNAL TRANSDUCTION;

ANIMALS; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS PROTEINS; DISEASE MODELS, ANIMAL; ETHOSUXIMIDE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; MUTATION; PHENOTYPE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84942770356     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/s13024-015-0051-6     Document Type: Erratum

References (55)

1. Narayan P, Ehsani S, Lindquist S. Combating neurodegenerative disease with chemical probes and model systems. Nat Chem Biol. 2014;10:911-20.
2. Link CD. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1995;92:9368-72.
3. Nass R, Miller DM, Blakely RD. C. elegans: a novel pharmacogenetic model to study Parkinson's disease. Parkinsonism Relat Disord. 2001;7:185-91.
4. Satyal SH, Schmidt E, Kitagawa K, Sondheimer N, Lindquist S, Kramer JM, et al. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2000;97:5750-5.
5. van Ham TJ, Breitling R, Swertz MA, Nollen EA. Neurodegenerative diseases: lessons from genome-wide screens in small model organisms. EMBO Mol Med. 2009;1:360-70.
6. Chen X, Burgoyne RD. Identification of common genetic modifiers of neurodegenerative diseases from an integrative analysis of diverse genetic screens in model organisms. BMC Genomics. 2012;13:71.
7. Zhang M, Luo G, Zhou Y, Wang S, Zhong Z. Phenotypic screens targeting neurodegenerative diseases. J Biomol Screen. 2014;19:1-16.
8. Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, Edison P, et al. Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov. 2012;11:833-46.
9. Lublin A, Link C. Alzheimer's disease drug discovery: screening using as a model for beta-amyloid peptide-induced toxicity. Drug Discov Today Technol. 2013;10:e115-9.
10. McCormick AV, Wheeler JM, Guthrie CR, Liachko NF, Kraemer BC. Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity. Biol Psychiatry. 2013;73:464-71.
11. Sleigh JN, Buckingham SD, Esmaeili B, Viswanathan M, Cuppen E, Westlund BM, et al. A novel Caenorhabditis elegans allele, smn-1(cb131), mimicking a mild form of spinal muscular atrophy, provides a convenient drug screening platform highlighting new and pre-approved compounds. Hum Mol Genet. 2011;20:245-60.
12. Wolozin B, Gabel C, Ferree A, Guillily M, Ebata A. Watching worms whither: modeling neurodegeneration in C. elegans. Prog Mol Biol Transl Sci. 2011;100:499-514.
13. Voisine C, Varma H, Walker N, Bates EA, Stockwell BR, Hart AC. Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans. PLoS One. 2007;2:e504.
14. Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H, et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet. 2005;37:349-50.
15. Tauffenberger A, Julien C, Parker JA. Evaluation of longevity enhancing compounds against transactive response DNA-binding protein-43 neuronal toxicity. Neurobiol Aging. 2013;34:2175-82.
16. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int. 2009;54:111-8.
17. Bizat N, Peyrin JM, Haik S, Cochois V, Beaudry P, Laplanche JL, et al. Neuron dysfunction is induced by prion protein with an insertional mutation via a Fyn kinase and reversed by sirtuin activation in Caenorhabditis elegans. J Neurosci. 2010;30:5394-403.
18. Kashyap SS, Johnson JR, McCue HV, Chen X, Edmonds MJ, Ayala M, et al. Caenorhabditis elegans dnj-14, the orthologue of the DNAJC5 gene mutated in adult onset neuronal ceroid lipofuscinosis, provides a new platform for neuroprotective drug screening and identifies a SIR-2.1-independent action of resveratrol. Hum Mol Genet. 2014;23:5916-27.
19. Noskova L, Stranecky V, Hartmannova H, Pristoupilova A, Baresova V, Ivanek R, et al. Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. Am J Hum Genet. 2011;89:241-52.
20. Benitez BA, Alvarado D, Cai Y, Mayo K, Chakraverty S, Norton J, et al. Exome-sequencing confirms DNAJC5 mutations as cause of adult neuronal ceroid-lipofuscinosis. PLoS One. 2011;6:e26741.
21. Velinov M, Dolzhanskaya N, Gonzalez M, Powell E, Konidari I, Hulme W, et al. Mutations in the gene DNAJC5 cause autosomal dominant Kufs disease in a proportion of cases: study of the Parry family and 8 other families. PLoS One. 2012;7:e29729.
22. Cadieux-Dion M, Andermann E, Lachance-Touchette P, Ansorge O, Meloche C, Barnabe A, et al. Recurrent mutations in DNAJC5 cause autosomal dominant Kufs disease. Clin Genet. 2013;83:571-5.
23. Zinsmaier KE, Eberle KK, Buchner E, Walter N, Benzer S. Paralysis and early death in cysteine string protein mutants of Drosophila. Science. 1994;263:977-80.
24. Chamberlain LH, Burgoyne RD. Cysteine-string protein: the chaperone at the synapse. J Neurochem. 2000;74:1781-9.
25. Sharma M, Burre J, Sudhof TC. CSPalpha promotes SNARE-complex assembly by chaperoning SNAP-25 during synaptic activity. Nat Cell Biol. 2011;13:30-9.
26. Sharma M, Burre J, Sudhof TC. Proteasome inhibition alleviates SNARE-dependent neurodegeneration. Sci Transl Med. 2012;4:147ra113.
27. Burgoyne RD, Morgan A. Chaperoning the SNAREs: a role in preventing neurodegeneration? Nat Cell Biol. 2011;13:8-9.
28. Fernandez-Chacon R, Wolfel M, Nishimune H, Tabares L, Schmitz F, Castellano-Munoz M, et al. The synaptic vesicle protein CSP alpha prevents presynaptic degeneration. Neuron. 2004;42:237-51.
29. Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ, Schellenberg GD. Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci U S A. 2003;100:9980-5.
30. Crunelli V, Leresche N. Block of thalamic T-type Ca(2+) channels by ethosuximide is not the whole story. Epilepsy Curr. 2002;2:53-6.
31. Steger KA, Shtonda BB, Thacker C, Snutch TP, Avery L. The C. elegans T-type calcium channel CCA-1 boosts neuromuscular transmission. J Exp Biol. 2005;208:2191-203.
32. Gems D, Riddle DL. Defining wild-type life span in Caenorhabditis elegans. J Gerontol A Biol Sci Med Sci. 2000;55:B215-9.
33. Cabreiro F, Au C, Leung KY, Vergara-Irigaray N, Cocheme HM, Noori T, et al. Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell. 2013;153:228-39.
34. Murphy CT, McCarroll SA, Bargmann CI, Fraser A, Kamath RS, Ahringer J, et al. Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature. 2003;424:277-83.
35. Henderson ST, Johnson TE. Daf-16 integrates developmental and environmental inputs to mediate aging in the nematode Caenorhabditis elegans. Curr Biol. 2001;11:1975-80.
36. Salih DA, Brunet A. FoxO transcription factors in the maintenance of cellular homeostasis during aging. Curr Opin Cell Biol. 2008;20:126-36.
37. Kang ML, Kwon JS, Kim MS. Induction of neuronal differentiation of rat muscle-derived stem cells in vitro using basic fibroblast growth factor and ethosuximide. Int J Mol Sci. 2013;14:6614-23.
38. Park SH, Kukushkin Y, Gupta R, Chen T, Konagai A, Hipp MS, et al. PolyQ proteins interfere with nuclear degradation of cytosolic proteins by sequestering the Sis1p chaperone. Cell. 2013;154:134-45.
39. Collins JJ, Evason K, Pickett CL, Schneider DL, Kornfeld K. The anticonvulsant ethosuximide disrupts sensory function to extend C elegans lifespan. PLoS Genet. 2008;4:e1000230.
40. Bargmann CI. Neurobiology of the Caenorhabditis elegans genome. Science. 1998;282:2028-33.
41. Evason K, Huang C, Yamben I, Covey DF, Kornfeld K. Anticonvulsant medications extend worm life-span. Science. 2005;307:258-62.
42. Choi H, Schneider H, Klum S, Chandler-Brown D, Kaeberlein M, Shamieh L. UV-Photoconversion of ethosuximide from a longevity-promoting compound to a potent toxin. PLoS One. 2013;8:e82543.
43. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. Opposing activities protect against age-onset proteotoxicity. Science. 2006;313:1604-10.
44. Zhang T, Mullane PC, Periz G, Wang J. TDP-43 neurotoxicity and protein aggregation modulated by heat shock factor and insulin/IGF-1 signaling. Hum Mol Genet. 2011;20:1952-65.
45. Morley JF, Brignull HR, Weyers JJ, Morimoto RI. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2002;99:10417-22.
46. Cohen E, Paulsson JF, Blinder P, Burstyn-Cohen T, Du D, Estepa G, et al. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell. 2009;139:1157-69.
47. Tepper RG, Ashraf J, Kaletsky R, Kleemann G, Murphy CT, Bussemaker HJ. PQM-1 complements DAF-16 as a key transcriptional regulator of DAF-2-mediated development and longevity. Cell. 2013;154:676-90.
48. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature. 2002;419:316-21.
49. Mojsilovic-Petrovic J, Nedelsky N, Boccitto M, Mano I, Georgiades SN, Zhou W, et al. FOXO3a is broadly neuroprotective in vitro and in vivo against insults implicated in motor neuron diseases. J Neurosci. 2009;29:8236-47.
50. Jiang M, Wang J, Fu J, Du L, Jeong H, West T, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med. 2012;18:153-8.
51. Pino E, Amamoto R, Zheng L, Cacquevel M, Sarria JC, Knott GW, et al. FOXO3 determines the accumulation of alpha-synuclein and controls the fate of dopaminergic neurons in the substantia nigra. Hum Mol Genet. 2014;23:1435-52.
52. Goren MZ, Onat F. Ethosuximide: from bench to bedside. CNS Drug Rev. 2007;13:224-39.
53. Edmonds MJ, Morgan A. A systematic analysis of protein palmitoylation in Caenorhabditis elegans. BMC Genomics. 2014;15:841.
54. Zhang Y, Chen D, Smith MA, Zhang B, Pan X. Selection of reliable reference genes in Caenorhabditis elegans for analysis of nanotoxicity. PLoS One. 2012;7:e31849.
55. Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J R Stat Soc Ser B-Methodol. 1995;57:289-300.